These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31518885)

  • 1. US physicians' decision-making during buprenorphine-naloxone treatment: Conjoint analyses of dose and office visit adjustments based on patient progress.
    Knudsen HK; Lofwall MR; Lin LA; Walsh SL; Studts JL
    Drug Alcohol Depend; 2019 Nov; 204():107490. PubMed ID: 31518885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicians' Decision-making When Implementing Buprenorphine With New Patients: Conjoint Analyses of Data From a Cohort of Current Prescribers.
    Knudsen HK; Lofwall MR; Walsh SL; Havens JR; Studts JL
    J Addict Med; 2018; 12(1):31-39. PubMed ID: 28914663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decline in Buprenorphine/Naloxone Prescriptions in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail.
    Soper R; Appajosyula S; Deximo C
    Adv Ther; 2018 Apr; 35(4):457-466. PubMed ID: 29623562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.
    Gunderson EW; Wang XQ; Fiellin DA; Bryan B; Levin FR
    Addict Behav; 2010 May; 35(5):537-40. PubMed ID: 20106601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends In Buprenorphine Prescribing By Physician Specialty.
    Wen H; Borders TF; Cummings JR
    Health Aff (Millwood); 2019 Jan; 38(1):24-28. PubMed ID: 30615523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barriers and attitudes reported by Canadian emergency physicians regarding the initiation of buprenorphine/naloxone in the emergency department for patients with opioid use disorder.
    Savage T; Ross M
    CJEM; 2022 Jan; 24(1):44-49. PubMed ID: 34564838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
    Srivastava A; Kahan M; Nader M
    Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
    Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS
    N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013.
    Turner L; Kruszewski SP; Alexander GC
    Am J Addict; 2015 Jan; 24(1):24-9. PubMed ID: 25823632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.
    Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM
    Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine/naloxone induction in a Canadian emergency department with rapid access to community-based addictions providers.
    Hu T; Snider-Adler M; Nijmeh L; Pyle A
    CJEM; 2019 Jul; 21(4):492-498. PubMed ID: 31006398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting.
    Leshner AI
    Drug Alcohol Depend; 2003 May; 70(2 Suppl):S103-4. PubMed ID: 12738354
    [No Abstract]   [Full Text] [Related]  

  • 16. Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study.
    Sullivan JG; Webster L
    Clin Ther; 2015 May; 37(5):1064-75. PubMed ID: 25823919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
    N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of Simulated Adherence in Long-Term Buprenorphine/Naloxone Treatment Patients.
    Rahman N; Janardhanan A; Shikalgar S; Pirkhan MA; Canner J; Skipwith C; Noor-E-Alam M
    Subst Use Misuse; 2024; 59(9):1275-1279. PubMed ID: 37950394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.
    Bhatraju EP; Grossman E; Tofighi B; McNeely J; DiRocco D; Flannery M; Garment A; Goldfeld K; Gourevitch MN; Lee JD
    Addict Sci Clin Pract; 2017 Feb; 12(1):7. PubMed ID: 28245872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.